The 10-second takeaway
For the quarter ended March 31 (Q1), Pacira Pharmaceuticals beat expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP loss per share contracted.
Margins increased across the board.
Pacira Pharmaceuticals booked revenue of $7.8 million. The four analysts polled by S&P Capital IQ expected net sales of $7.5 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $3.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.47. The four earnings estimates compiled by S&P Capital IQ forecast -$0.40 per share. GAAP EPS were -$0.47 for Q1 versus -$0.98 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 16.8%, 1,170 basis points better than the prior-year quarter. Operating margin was -142.7%, 4,170 basis points better than the prior-year quarter. Net margin was -152.4%, 10,060 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $8.1 million. On the bottom line, the average EPS estimate is -$0.48.
Next year's average estimate for revenue is $34.7 million. The average EPS estimate is -$1.37.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pacira Pharmaceuticals is buy, with an average price target of $16.20.
The drug and health-care investing landscape is littered with also-rans and a few major winners. Is Pacira Pharmaceuticals the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Pacira Pharmaceuticals to My Watchlist.